Glucagon

Main evidence: Human clinical trials. Updated 2026-10-28.

What research and users report, not a recommendation or medical advice. Many of these products are not approved for human use. Ask your doctor. Packs report what sources say, each with its evidence label. A claim labelled community, educator, manufacturer or animal has not been validated in humans.

Summary

This information-only pack reviews Australian GlucaGen HypoKit labeling, clinical evidence, safety and registration status; it is not an individualized treatment plan.

Safety and cautions

Safety statements are source-specific and should not be generalized across products, formulations or routes.

Australian legal status

The TGA's public register shows a current registered GlucaGen HypoKit presentation. Registration is product-specific and does not establish present stock or availability. This pack does not assess non-registered or compounded glucagon products.

What the sources say

In two randomized crossover non-inferiority studies involving 161 adults with type 1 diabetes and insulin-induced severe hypoglycaemia, a ready-to-use glucagon autoinjector was non-inferior to a reconstituted glucagon emergency kit for glucose recovery within 30 minutes. The authors disclose industry relationships, and induced hypoglycaemia studies do not by themselves establish real-world performance for every glucagon product. (Human clinical trials; Christiansen MP et al., "Comparison of a ready-to-use liquid glucagon injection administered by autoinjector to glucagon emergency kit…" PubMed record (journal issue October 2021; page checked 2026-10-28)., 2026-10-28)
Australian GlucaGen HypoKit product information identifies treatment of severe hypoglycaemic reactions in people with diabetes using insulin or oral glucose-lowering medicines, and adult diagnostic use to reduce gastrointestinal motility. These are product-label uses, not a general endorsement of other glucagon products or wellness use. (Manufacturer information; Novo Nordisk, Australian Product Information: GlucaGen HypoKit (VV-LAB-098357), revision 2021-09-21., 2021-09-21)
Glucagon raises blood glucose mainly by mobilizing liver glycogen; the Australian product information says it may have little or no effect when hepatic glycogen is depleted, including prolonged fasting, chronic hypoglycaemia or alcohol-induced hypoglycaemia. (Manufacturer information; Novo Nordisk, Australian Product Information: GlucaGen HypoKit (VV-LAB-098357), revision 2021-09-21., 2021-09-21)
The Australian product information lists nausea, vomiting and abdominal pain among adverse effects, and contraindicates use in phaeochromocytoma, insulinoma, glucagonoma or known hypersensitivity. It also warns that adequate liver glycogen is needed for effect and that rebound hypoglycaemia can occur in insulinoma or glucagonoma. (Manufacturer information; Novo Nordisk, Australian Product Information: GlucaGen HypoKit (VV-LAB-098357), revision 2021-09-21., 2021-09-21)
The Australian product information says the reconstituted solution is unstable, has no preservative, and must be used once only; this product-specific kit instruction is not a general reconstitution rule for other peptide products. (Manufacturer information; Novo Nordisk, Australian Product Information: GlucaGen HypoKit (VV-LAB-098357), revision 2021-09-21., 2021-09-21)

Sources

Dosing, stacking and protocol details are not published here.